How did ABCL's revenue and expenses shift in Q4 2024 compared to previous quarters?

**AbCellera Biologics Inc. (ABCL) experienced a decline in revenue and an increase in expenses in Q4 2024 compared to the previous quarter.**

1. **Revenue Shift**:
- ABCL's revenue in Q4 2024 was $6.51 million.
- In the previous quarter (Q3 2024), the revenue was $6.6 million.
- This indicates a decrease in revenue, which could be due to various factors such as market conditions, business strategy, or industry trends.
2. **Expense Shift**:
- The net loss in Q4 2024 was $51.11 million.
- In Q3 2024, the net loss was $28.61 million.
- This suggests a significant increase in net loss, which might be attributed to higher expenses or reduced revenue compared to the previous quarter.
3. **Comparison with FY 2023**:
- ABCL's revenue for the full year 2024 was approximately $28.83 million, which is lower than the revenue of $38.03 million in 2023.
- The net loss for the full year 2024 was $162.86 million, compared to $146.4 million in 2023.
- This indicates a decline in revenue and a increase in net loss over the full year, which is consistent with the trend observed in Q4 2024.

In summary, ABCL faced a challenging quarter in Q4 2024, with both revenue and net loss figures indicating a decline compared to the immediate previous quarter and the full year preceding. This trend suggests that ABCL needs to address its revenue generation and cost management strategies to improve financial performance.